HHS OIG and HRSA Are Mum About 340B Manufacturer Civil Monetary Penalties and Violation Notices

screenshot of HRSA correspondence to stakeholders web page
HRSA and OIG have no comment on the status of drug manufacturer civil monetary penalties and violation letters stemming from denials of 340B pricing to covered entities that use contract pharmacies.

The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing to offer

Read More »

AHA Again Blasts PhRMA and NACHC’s Alliance to Remake 340B

screenshot of the AHA blog
The AHA slammed PhRMA and NACHC's 340B reform alliance again, this time in its blog and related talking points.

The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar bottom lines.”

Read More »

Novartis to Appeals Court: Our New 340B Contract Pharmacy Policy Doesn’t Affect Our Case Before You

Novartis wordmark on a building
Drugmaker Novartis is offering refunds to 340B covered entities on certain purchases of two radiopharmaceuticals.

Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.

If the court disagrees,

Read More »

News Alert

Novartis Toughens its Conditions on 340B Pricing for Hospitals

Novartis wordmark on a building
Novartis announced today that it will let hospitals without an in-house pharmacy pick just one contract pharmacy location where Novartis will ship 340B discounted drugs.

Drug manufacturer Novartis this afternoon significantly beefed up its conditions on 340B pricing for hospitals.

Two others—GlaxoSmithKline and Pfizer—made similar moves on Friday. Novartis is the sixth to stiffen its 340B pricing policy since a federal appeals court ruled

Read More »

Breaking News

GSK Extends 340B Pricing Conditions to all Covered Entities and all Products

GlaxoSmithKline wordmark and GSK logo on a building
GlaxoSmithKline and Pfizer announced updates to their 340B contract pharmacy policies to comply with new state laws that will take effect in July.

UPDATE Friday, March 31, 2023, 6:45 p.m. EDT—Story updated with comment from the National Association of Community Health Centers.


Drug manufacturer GlaxoSmithKline this afternoon announced a major expansion of its conditions on 340B pricing in the contract

Read More »

News Alert

Pfizer Is the Second Drug Maker This Week to Tighten Limits on 340B Sales to Hospitals

Pfizer company name on a building
Drug manufacturer Pfizer stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz.

Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.

Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer

Read More »

ASAP 340B Hires Executive Director and Publishes FAQ in Response to Questions and Criticism

ASAP 340B partnership wordmark
ASAP 340B this week announced it hired an executive director and published an FAQ that responds to questions and criticism.

ASAP 340B, the nonprofit group that the drug industry and health centers formed to help advance their joint plan to remake the 340B program, has hired an executive director and published an FAQ that responds to questions and criticism. “There

Read More »

AIDS Healthcare Foundation Protests Against PhRMA/NACHC Alliance During 340B Coalition Conference

Protesters carry placards in support of the 340B drug pricing program and AHF
AIDS Healthcare Foundation held a protest march Tuesday at the 340B Coalition winter conference in California against the PhRMA/NACHC alliance to change the 340B program.

AIDS Healthcare Foundation held two demonstrations Tuesday—one outdoors and loud, the other indoors and silent—at the 340B Coalition winter conference in California to protest against the new drug industry/community health center alliance to change the 340B program.

“Let’s be clear.

Read More »

News Alert

AbbVie Puts Squeeze on 340B Pricing for Hospitals Akin to J&J and Amgen’s Recent Moves

AbbVie facility gate
AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals, along the lines of Amgen and Johnson & Johnson's recent moves.

Drug manufacturer AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals.

AbbVie has not yet responded to a request for comment about the changes. Non-hospital covered entities continue to be exempt from AbbVie’s pricing restrictions.

Drug manufacturers

Read More »

RWC-340B Opposes and Hemophilia Alliance Questions PhRMA and NACHC’s Push to Remake 340B

RWC-340B Hemophilia Alliance wordmarks
RWC-340B rejected and Hemophilia Alliance criticized PhRMA and NACHC's joint plan to restructure the 340B program.

Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net providers.”

Hemophilia

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live